TriangleNCT00897910 · REGISTRY CONDITION SEARCH
Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma
Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.
- Phase
- Not reported
- Status at capture
- TERMINATED
- Registry last update
- 2016-01-11
RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about T cells and plan better treatment for multiple myeloma. PURPOSE: This research study is looking at T cells in blood and bone marrow samples from patients with multiple myeloma.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Who could take part
- eligibility Criteria
- DISEASE CHARACTERISTICS: * Diagnosis of multiple myeloma PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sampling Method
- NON_PROBABILITY_SAMPLE
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
- study Population
- Patients with a diagnosis of multiple myeloma identified from the outpatient clinics or inpatient service of Karmanos Cancer Center by physicians in the Department of Hematology and Medical Oncology.
Treatment arms and interventions
- interventions
- description
- Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
- name
- flow cytometry
- type
- OTHER
- description
- Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
- name
- immunoenzyme technique
- type
- OTHER
- description
- Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
- name
- laboratory biomarker analysis
- type
- OTHER
Study design
- observational Model
- CASE_ONLY
- time Perspective
- PROSPECTIVE
Enrollment
- count
- 6
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- measure
- Percentage of Myeloma-specific T Cells ex Vivo Expanded Using Flow Cytometry
- time Frame
- Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
- secondary Outcomes
- measure
- Cell Counts of Myeloma-specific T Cells ex Vivo Expanded Before and After CD3/CD28 Stimulation
- time Frame
- Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
Full study description
- brief Summary
- RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about T cells and plan better treatment for multiple myeloma. PURPOSE: This research study is looking at T cells in blood and bone marrow samples from patients with multiple myeloma.
- detailed Description
- OBJECTIVES: Primary * To evaluate the feasibility of expanding myeloma-specific T cells using autologous ex vivo expanded B cells loaded with myeloma antigens as antigen-presenting cells (B-APCs) in peripheral blood and bone marrow samples from patients with multiple myeloma. Secondary * To examine the feasibility of selecting and expanding myeloma-specific T cells ex vivo using interferon γ release and CD3/CD28 stimulation. OUTLINE: Peripheral blood and bone marrow samples are collected periodically for laboratory studies. Samples are analyzed to assess the feasibility of expanding autologous B cells ex vivo using CD40L and IL-4; the antigen-presenting phenotype of autologous B-cell antigen-presenting cells (B-APCs) using flow cytometry; and the antigen-presenting function of B-APCs using ELISPOT and chromium-release assay. Myeloma-specific interferon γ secreting T cells are isolated and selected using Miltenyi beads. The selected myeloma-specific T cells are expanded ex vivo using anti CD3/CD28 beads.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-1336d216cbd1bbff780dac70
- edge id
- nct-edge-f33a3867daddb3720e02
- requested nct id
- NCT00897910
- primary nct id
- NCT00897910
- source kind
- ctgov_condition_query
- source record id
- Source null
- source file sha256
- 2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
- payload sha256
- 06461092367de3adbb895fcfebc5cb354db24efaeb287fec92b4424cb77d1c49
- payload
- clinical indication matching status
- condition_index_match_asserted_by_registry_not_reviewed
- end exclusive
- true
- id
- nct-edge-f33a3867daddb3720e02
- link basis
- returned_by_explicit_condition_and_posted_results_filter_query
- nct id
- NCT00897910
- occurrences
- context exact
- NCT00897910
- end
- 11
- exact text
- NCT00897910
- start
- 0
- offset unit
- unicode_code_points
- query cond
- Plasma Cell Neoplasms
- query disease state id
- ds-plasma-cell-neoplasms
- source file
- /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
- source file sha256
- 2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
- source json pointer
- /studies/290/protocolSection/identificationModule/nctId
- source kind
- ctgov_condition_query
- source record id
- Source null
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- a81083159d153fa21af60345dfc0b8984a89a41c28ed30ecdf7aeeb4f0aa0b11
Preserved source evidence · Not medical advice